Sprycel News and Research

RSS
On June 28, 2006, the FDA granted accelerated approval of SPRYCEL for the treatment of adults in all three phases of CML (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec. The FDA also granted full approval of SPRYCEL for the treatment of adults with Ph+ ALL with resistance or intolerance to prior therapy. SPRYCEL is the first approved oral tyrosine kinase inhibitor that, at nanomolar concentrations, inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß kinases. The active ingredient of SPRYCEL is dasatinib. Dasatinib reduces the activity of one or more proteins responsible for the uncontrolled growth of the leukemia cells of patients with CML or Ph+ ALL.
Rutgers study uncovers new mechanism linked to Alzheimer's and traumatic brain injury

Rutgers study uncovers new mechanism linked to Alzheimer's and traumatic brain injury

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

Researchers identify new class of drugs that slows aging process

Researchers identify new class of drugs that slows aging process

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

UCLA's Jonsson Comprehensive Cancer Center named one of nation's top 12 cancer centers

UCLA's Jonsson Comprehensive Cancer Center named one of nation's top 12 cancer centers

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

New library for development of targeted cancer drugs

New library for development of targeted cancer drugs

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Medco announces new offerings within Advanced Oncology Solutions

Medco announces new offerings within Advanced Oncology Solutions

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

New drug appears to help patients with chronic myeloid leukemia

New drug appears to help patients with chronic myeloid leukemia